FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167310611> ?p ?o ?g. }

• W2167310611 endingPage "1436" @default.
• W2167310611 startingPage "1427" @default.
• W2167310611 abstract "After two decades of interferon (IFN) treatment in myeloma patients and many randomised clinical trials, no definite proof of its benefits exists. This meta-analysis of all available relevant published data tests the differences between IFN and control arms in a large patient population and addresses the issue of cost-effectiveness.Meta-analysis was performed on 17 trials among 2333 patients who received IFN-chemotherapy induction treatment or chemotherapy alone and on 13 trials among 1615 patients on IFN maintenance therapy or without treatment. Response rates and parameters of published Kaplan Meier relapse-free and overall survival curves were analysed.Patients in IFN arms showed significantly better results in all investigated parameters: IFN-chemotherapy induction treatment yielded 6.6% higher response rates (2P < 0.002) as well as 4.8-month and 3.1-month prolongations of relapse-free (P < 0.01) and overall survival (P < 0.01), respectively. Interferon maintenance therapy lead to 4.4-month (P < 0.01) and 7.0-month (P < 0.01) prolongations of relapse-free and overall survival, respectively. Meta-analysis of all IFN trials combined resulted in 4.6-month and 3.7-month IFN-related gains in relapse-free and overall survival, respectively. As early as 6 and 12 months after the start of IFN treatment, percentages of cumulative relapse-free and overall survival were always significantly higher in IFN trial arms. IFN drug expenses for a one-year survival gain, as determined from AUCs of best-fitted Gompertz functions of IFN and control survival curves, were estimated to be US$42,482.28 for induction therapy and US$18,968.16 for maintenance treatment.Significantly superior outcomes were consistently found in IFN trial arms by meta-analysis of published data. These results are in accordance with a concomittantly conducted meta-analysis on individual patient data but were much easier to accrue. Taking all our results into account. i.e., the consistently significant, although limited, improvement of clinical outcomes and its acceptable cost-effectiveness, IFN treatment of patients with multiple myeloma seems worthwhile to be considered." @default.
• W2167310611 created "2016-06-24" @default.
• W2167310611 creator A5028662013 @default.
• W2167310611 creator A5057395053 @default.
• W2167310611 date "2000-11-01" @default.
• W2167310611 modified "2023-10-02" @default.
• W2167310611 title "Interferon-α treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients" @default.
• W2167310611 cites W1742647530 @default.
• W2167310611 cites W1942759266 @default.
• W2167310611 cites W1965941534 @default.
• W2167310611 cites W1988257437 @default.
• W2167310611 cites W1992583368 @default.
• W2167310611 cites W2004557741 @default.
• W2167310611 cites W2006445589 @default.
• W2167310611 cites W2006669604 @default.
• W2167310611 cites W2010321586 @default.
• W2167310611 cites W2014207161 @default.
• W2167310611 cites W2015533960 @default.
• W2167310611 cites W2018152980 @default.
• W2167310611 cites W2027705028 @default.
• W2167310611 cites W2028429660 @default.
• W2167310611 cites W2038504752 @default.
• W2167310611 cites W2045378060 @default.
• W2167310611 cites W2050923834 @default.
• W2167310611 cites W2054100499 @default.
• W2167310611 cites W2079668255 @default.
• W2167310611 cites W2087068946 @default.
• W2167310611 cites W2107328434 @default.
• W2167310611 cites W2118443286 @default.
• W2167310611 cites W2141293193 @default.
• W2167310611 cites W2142192424 @default.
• W2167310611 cites W2178317066 @default.
• W2167310611 cites W2179977652 @default.
• W2167310611 cites W219378421 @default.
• W2167310611 cites W2267218466 @default.
• W2167310611 cites W2269407420 @default.
• W2167310611 cites W2281141582 @default.
• W2167310611 cites W2294564449 @default.
• W2167310611 cites W2508058084 @default.
• W2167310611 cites W2901368272 @default.
• W2167310611 cites W552834 @default.
• W2167310611 doi "https://doi.org/10.1023/a:1026548226770" @default.
• W2167310611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11142483" @default.
• W2167310611 hasPublicationYear "2000" @default.
• W2167310611 type Work @default.
• W2167310611 sameAs 2167310611 @default.
• W2167310611 citedByCount "159" @default.
• W2167310611 countsByYear W21673106112012 @default.
• W2167310611 countsByYear W21673106112013 @default.
• W2167310611 countsByYear W21673106112014 @default.
• W2167310611 countsByYear W21673106112015 @default.
• W2167310611 countsByYear W21673106112016 @default.
• W2167310611 countsByYear W21673106112017 @default.
• W2167310611 countsByYear W21673106112018 @default.
• W2167310611 countsByYear W21673106112019 @default.
• W2167310611 countsByYear W21673106112021 @default.
• W2167310611 countsByYear W21673106112022 @default.
• W2167310611 countsByYear W21673106112023 @default.
• W2167310611 crossrefType "journal-article" @default.
• W2167310611 hasAuthorship W2167310611A5028662013 @default.
• W2167310611 hasAuthorship W2167310611A5057395053 @default.
• W2167310611 hasBestOaLocation W21673106111 @default.
• W2167310611 hasConcept C10515644 @default.
• W2167310611 hasConcept C126322002 @default.
• W2167310611 hasConcept C143998085 @default.
• W2167310611 hasConcept C168563851 @default.
• W2167310611 hasConcept C2776364478 @default.
• W2167310611 hasConcept C2776694085 @default.
• W2167310611 hasConcept C2908647359 @default.
• W2167310611 hasConcept C50382708 @default.
• W2167310611 hasConcept C535046627 @default.
• W2167310611 hasConcept C71924100 @default.
• W2167310611 hasConcept C95190672 @default.
• W2167310611 hasConcept C99454951 @default.
• W2167310611 hasConceptScore W2167310611C10515644 @default.
• W2167310611 hasConceptScore W2167310611C126322002 @default.
• W2167310611 hasConceptScore W2167310611C143998085 @default.
• W2167310611 hasConceptScore W2167310611C168563851 @default.
• W2167310611 hasConceptScore W2167310611C2776364478 @default.
• W2167310611 hasConceptScore W2167310611C2776694085 @default.
• W2167310611 hasConceptScore W2167310611C2908647359 @default.
• W2167310611 hasConceptScore W2167310611C50382708 @default.
• W2167310611 hasConceptScore W2167310611C535046627 @default.
• W2167310611 hasConceptScore W2167310611C71924100 @default.
• W2167310611 hasConceptScore W2167310611C95190672 @default.
• W2167310611 hasConceptScore W2167310611C99454951 @default.
• W2167310611 hasIssue "11" @default.
• W2167310611 hasLocation W21673106111 @default.
• W2167310611 hasLocation W21673106112 @default.
• W2167310611 hasOpenAccess W2167310611 @default.
• W2167310611 hasPrimaryLocation W21673106111 @default.
• W2167310611 hasRelatedWork W2123826310 @default.
• W2167310611 hasRelatedWork W2337677096 @default.
• W2167310611 hasRelatedWork W2896492909 @default.
• W2167310611 hasRelatedWork W3011827526 @default.
• W2167310611 hasRelatedWork W3012824765 @default.
• W2167310611 hasRelatedWork W3024123676 @default.
• W2167310611 hasRelatedWork W3200659145 @default.

• next